

Roche A Leading Pharmaceuticals Pipeline

*Dr. Eduard Holdener, Chief Medical Officer Roche
March 2007*



This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com


All mentioned trademarks are legally protected

Major initiatives over the past 5 years



Strengthened business base and focused activities

Focus on medically differentiated products

	2001	2006
Top 10 as % of pharma sales	56 %	67 %
Key products % of pharma sales	27 %	59 %





Building new therapeutic franchises and focus R&D efforts



ONC: Oncology; IAB: Inflammation / Autoimmune / Bone; MVD: Metabolic and Vascular Diseases; CNS: Central Nervous System, VD: Viral Diseases

Clinical Trials Overview and Disease Biology Areas

Appendix



Oncology: A leading phase III pipeline

Targeting main tumor types and use in early intervention



	ADJUVANT	MAINT.	1 st LINE		2 nd LINE
Filed or to file soon			Tarceva pancreatic Ca	Avastin NSCLC	Avastin mBC
Ongoing	Xeloda adjuvant BC	Tarceva & Avastin NSCLC maintenance	Xeloda gastric Ca	Avastin mCRC 1 st line ext.	Xeloda mCRC 2 nd line combo
	Xeloda adjuvant CC combo	MabThera NHL maintenance	Herceptin mBC combo hormonal	Xeloda mCRC 1 st line combo	MabThera relapsed CLL
	Avastin adjuvant rectal Ca		Avastin pancreatic Ca	Avastin NSCLC 1 st line ext.	Avastin prostate Ca
	Avastin adjuvant CC		Avastin ovarian Ca	MabThera 1 st line CLL	Tarceva & Avastin NSCLC 2 nd line
	Tarceva adjuvant NSCLC		Herceptin gastric Ca	Tarceva NSCLC 1 st line	Avastin mBC 2 nd line
To start soon	Avastin adjuvant NSCLC	Avastin adjuvant BC	Avastin & Herceptin mBC 1 st line ext.		

7

Roche in autoimmune diseases

Building a new therapeutic franchise



MabThera

- Launched in RA anti-TNF inadequate responders in US and EU
- Comprehensive clinical program to maximize potential

Actemra

- Filed in Japan
- Broad international phase III program, global filing in 2007

CellCept

- Phase III in Lupus Nephritis completed recruitment, filing 2007

MabThera

- Phase III in LN, PPMS, ANCA ass. vasculitis and SLE ongoing

Ocrelizumab

- Phase II trial in RA met primary and secondary endpoints, to be presented at ACR '06
- Phase III program in RA initiated
- Phase II / III in RRMS and Lupus in preparation

R1503 (p38 kinase inhibitor)

- Phase II initiated in Q4'05

MabThera

- Phase II in RRMS met primary endpoints

Phase 1

- 3 compounds in development for autoimmune diseases

8 phase III projects

2 phase II projects

8

Rheumatoid Arthritis

In the very late stage of clinical development

Anti-CD 20 franchise

MabThera/Rituxan

- Phase III in RA DMARD and MTX inadequate responders on track
 - filing EU in 2008
- Phase III for repeated treatment courses on track
 - filing in EU 2008

Ocrelizumab

- Phase III commenced

Actemra: First-in-class agent

- Japanese phase III in DMARD inadequate responders (IR) showed impressive results
 - filed in Japan
- Phase III in RA MTX IR, DMARD IR (RoW) recruitment completed
 - first trial (OPTION) met primary endpoint
- Global filing late 2007

Roche in virology

Building on our leading position in Hepatitis C

R1626 (Polymerase inhibitor)

- Phase II initiated
- Filing post 2010
- Promising phase I data presented at EASL and AASLD in 2006

R7025 (peg-IFN)

- Next generation pegylated interferon alpha
- in phase I
- licensed from Maxygen

R7227 (Protease inhibitor)

- in phase I (initiated January 2007)
- licensed from InterMune

R7128 (Polymerase inhibitor)

- in phase I
- licensed from Pharmasset

1 phase II project
3 phase I projects

Roche in metabolic / cardiovascular diseases

Major decision points within the near future



R1583 (GLP-1)

- Phase II data on immediate release formulation presented at ADA'06
- Start of phase II with sustained release formulation early 2007
- Filing 2010

R1440 (GKA)

- Phase II started Q4'05
- First phase II data available 2007
- Filing 2009

R1658 (CETP inhibitor)

- First phase II completed – efficacy and safety confirmed
- Phase II safety trial ongoing
- Go/ No go decision for phase III in 2007
- Filing post 2010

R1439

- Dual PPAR (α/γ) agonist
- Phase II initiated in Q4 2006
- Filing post 2010

Phase I

- 3 compounds in development for metabolic/ CV diseases

4 phase II projects
3 phase I projects

11

Cardiovascular diseases / dyslipidemia



JTT-705/ R1658

- Roche and Japan Tobacco signed agreement for development and commercialization in October 2004
 - Roche has exclusive worldwide rights, excluding Japan and Korea
- Clinical efficacy **data confirms benefits of CETP inhibition** in hyperlipidemia/ dyslipidemia
- **Well-tolerated**, with a similar overall safety profile to placebo
- Phase II in dyslipidemia (combination with pravastatin)
 - primary endpoint: percentage and absolute change from baseline at Week 12 in HDL-C level (efficacy)
 - already seen **encouraging efficacy data**
 - safety trial ongoing

Go/ no go decision for phase III in 2007

12

New pharma model: Disease Biology Areas (DBAs)

Alignment and focus



Disease Biology Areas (DBAs)

Idea ←————→ Market



- Initial focus on five DBAs
- Decisions made by Disease Biology Leadership Teams (DBLTs) against measurable metrics
- **Up to Proof of Concept:** DBLTs manage compound progression within respective DBA
- **After Proof of Concept:** DBLTs responsible for conducting scientific/ medical reviews and providing options to Pharma Leadership Team


- Clear focus
- More independent and flexible disease areas
- Faster and simpler decision processes

Streamlined decision making throughout drug lifecycle


Simpler, more transparent oversight



Today's model



New model



Decision Making Committees
 Decision Making Committees & Peer Reviews



We Innovate Healthcare



Clinical Trials Overview and Disease Biology Areas

Appendix

Avastin: Building standard of care, sustaining leadership

Effectively maximizing an asset



Main Indication		Status		Main Indication		Status		
NSCLC	1st line non-squamous	Avastin in Lung*	Recr. completed, Final analysis H1'07	mCRC	1st line	NO16966	Positive results Q3'06, Filing H1'07	
		ATLAS	Initiated Q4'05		Adjuvant CC		AVANT	Recr. to complete H1'07
	1st line squamous	AVASQ	Initiated Q3'06				NSABP C-08	Recr. completed
		2nd line	BRIDGE	Pilot initiated Q2'06	Adjuvant rectal Ca		E5204	Initiated Q1'06
Adjuvant NSCLC			BETA Lung	Initiated Q2'05		ECOG 1505	To initiate H1'07	
mBC	1st line HER2-negative	AVADO	Recr. to complete H1'07	RCC	1st line	AVOREN	Positive results Q4'06, Filing 2007	
		RIBBON-1	Initiated Q4'05, Global recruitment launched			CALGB 90206	Awaiting results	
	1st line HER2-positive	AVEREL	Initiated Q3'06	Pancreatic Ca	1st line	AVITA	Recr. completed	
		2nd line	RIBBON-2			Initiated Q1'06	Ovarian Ca	1st line
Adjuvant BC	HER2-negative		E2104	Pilot initiated Q4'05, Analysis Q1'07	2nd line	ICON7		Initiated Q4'06
		E5103	To initiate 2007		GOG 213	In preparation		
HER2-positive	006R/B-31R	In preparation	BO20289	To initiate 2007	Prostate Ca	Hormone refractory	CALGB 90401	Initiated Q2'05

* Formerly called AVAIL

Xeloda/ Tarceva/ MabThera/ Herceptin: Maximizing across the portfolio



Main Indications		Status			
Xeloda	Adjuvant CC	Combo Avastin	AVANT	Recr. to complete H1'07	
		Combo oxaliplatin	NO16968	Recr. completed, Final analysis end '07/early '08	
			NO 17629	Recr. completed	
Tarceva	NSCLC 1st line maintenance	Combo chemotherapy	SATURN	Initiated Q4'05, Recr. to complete '07	
			TITAN	Initiated Q4'05, Recr. to complete '07	
		Combo Avastin	ATLAS	Initiated Q4'05	
	NSCLC 2nd line	Combo Avastin	BETA Lung	Initiated Q2'05	
Adjuvant NSCLC		RADIANT	Initiated Q3'06		
MabThera	NHL maintenance 1st line	After MabThera induction	PRIMA	Initiated Q1'06, Recr. to complete H1'07	
			ML17102	Recr. completed	
	CLL 1st line		REACH	Recr. to complete end '07	
	CLL relapsed				
Herceptin	Gastric Ca		ToGA	Initiated Q3'05, Recr. to complete H2'07	
		Adjuvant BC	1yr vs. 2yrs treatment	HERA	Final analysis 2008/2009

Rheumatoid Arthritis/ Auto Immune

Major indications in phase III development

Main Indication		Status		Main Indication		Status	
Rheumatoid arthritis				Multiple sclerosis			
MabThera	MTX - inadequate responders	SERENE, SUNRISE MIRROR	Recr. completed	MabThera	PPMS	OLYMPUS	Recr. completed Q4'05
	MTX -naive	IMAGE	Initiated Q1'06		RRMS	HERMES	Met primary endpoint Q3'06. To be presented at AAN'07
	Combo Enbrel	TAME	Initiated Q2'06	Ocrelizumab	RRMS	Phase II or III	In discussion
Actemra	MTX (DMARD) - inadequate resp. or -naive	OPTION, TOWARD, AMBITION	Recr. completed, Final analysis by mid '07 (OPTION January '07)	Lupus nephritis			
	Anti-TNF inadequate resp.	RADIATE	Recr. completed, Final analysis by mid '07	MabThera		LUNAR	To complete recr. H2'07
	MTX inadequate responders	LITHE	Recr. completed	Ocrelizumab		Phase III	To initiate Q2'07
Ocrelizumab	MTX inadequate responders	Phase III	Initiated Q4'06	CellCept		Phase III	Recr. completed, Results (induction phase) H1'07
	Anti-TNF inadequate responders	Phase III	To initiate H1'07	SLE			
	X-ray study	Phase III	To initiate H1'07	MabThera		EXPLORER	To complete recr. Q1'07
ANCA ass. vasculitis				Ocrelizumab		Phase III	To initiate in Q2'07
MabThera		RAVE	Initiated Q4'04				

Metabolic and vascular diseases

Major decision points in 2007

Main Indications		Status	
Type 2 Diabetes			
R1440 (GKA)	Phase II	Initiated Q4'05 First phase II data available 2007 Filing 2009	
R1583 (GLP-1)	Phase II immediate release formulation	Presented at ADA'06	
	Phase II sustained release formulation	To initiate early 2007	
R1439 (PPAR α/γ)	Phase II	Initiated Q4'06	
R1579	Phase I	Ongoing	
R1511	Phase I	Ongoing	
Dyslipidemia			
R1658 (JTT-705)	Phase II efficacy	Encouraging data obtained H1'06	
	Phase II safety	Results by mid'07 Go/ No go decision for phase III in 2007 Filing 2010	